Price T Rowe Associates Inc. MD Has $172,000 Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Price T Rowe Associates Inc. MD increased its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA) by 20.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 33,870 shares of the company’s stock after acquiring an additional 5,801 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Humacyte were worth $172,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its position in Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock worth $28,294,000 after acquiring an additional 543,995 shares during the period. Brookstone Capital Management acquired a new position in shares of Humacyte in the 4th quarter valued at approximately $56,000. Wealth Effects LLC raised its position in shares of Humacyte by 89.1% in the 4th quarter. Wealth Effects LLC now owns 121,400 shares of the company’s stock valued at $613,000 after buying an additional 57,200 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Humacyte in the 4th quarter valued at approximately $99,000. Finally, Swiss National Bank raised its position in shares of Humacyte by 5.8% in the 4th quarter. Swiss National Bank now owns 172,100 shares of the company’s stock valued at $869,000 after buying an additional 9,400 shares in the last quarter. 44.71% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Humacyte news, Director Kathleen Sebelius bought 50,000 shares of Humacyte stock in a transaction on Tuesday, April 8th. The shares were purchased at an average cost of $1.32 per share, with a total value of $66,000.00. Following the acquisition, the director now directly owns 91,207 shares of the company’s stock, valued at $120,393.24. The trade was a 121.34% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Dale A. Sander bought 20,000 shares of Humacyte stock in a transaction on Thursday, April 10th. The shares were acquired at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. The trade was a 97.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 83,993 shares of company stock valued at $118,224 in the last ninety days. 5.10% of the stock is currently owned by insiders.

Humacyte Trading Up 18.5%

Shares of Humacyte stock opened at $2.24 on Friday. The firm has a market capitalization of $347.47 million, a PE ratio of -1.67 and a beta of 1.64. The firm’s 50 day moving average is $1.83 and its 200 day moving average is $3.48. Humacyte, Inc. has a 1 year low of $1.15 and a 1 year high of $9.97.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.46 million. As a group, research analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

HUMA has been the subject of several analyst reports. Benchmark dropped their target price on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Tuesday, May 13th. Finally, HC Wainwright initiated coverage on shares of Humacyte in a report on Wednesday. They set a “buy” rating and a $4.00 price target on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Humacyte presently has an average rating of “Buy” and a consensus price target of $11.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.